C Reactive Protein in Home Quarantined Coronavirus Disease 2019 (COVID -19) Patients.

C Reactive Protein Based Early Intervention for Home Quarantined COVID -19 Patients to Avoid Complications and Hospitalization.

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04935515

Enrollment

Registered

2021-06-23

Start date

2021-04-15

Completion date

2021-06-06

Last updated

2021-06-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID -19

Keywords

COVID -19;, Home quarantine;, C-Reactive Protein (CRP);, D-Dimer,, Early Intervention prior to onset of hypoxia

Brief summary

During the peak of the second COVID -19 wave, the hospitals were over-crowded. Many COVID -19 positive patients had to stay at home and reach out to their family physicians for guidance. Medical follow-up for these patients was a daunting challenge. As in - patient hospital facilities were not readily accessible due to over crowding, early objective tests to identify home quarantined patients prone to deterioration and timely medical intervention to avoid hospitalization were required. Based on early assessment of inflammatory markers like CRP and clinical signs like persistent high-grade fever, need-based early medical intervention was initiated in home quarantined COVID -19 patients prior to the onset of hypoxia, in order to avoid complications and hospitalization

Detailed description

25 home quarantined COVID -19 patients who contacted online for medical guidance underwent clinical and biochemical evaluation. Radiological evaluation was done only if indicated. Based on early objective biochemical tests like elevated CRP and clinical signs like persistent high-grade fever on the third or fourth day after onset of symptoms, early medical treatment was initiated prior to onset of hypoxia. All the 25 patients recovered without any complications and did not require hospitalization.

Interventions

DRUGOral Antibiotic, Antihistamine, Anti-inflammatory, Multivitamins

Oral Azithromycin , Cetirizine, Paracetamol, Zinc, Vitamin C, Vitamin D

DRUGOral low dose steroid

Low dose oral methyl prednisolone was added.

DRUGIntravenous Antibiotics with Low dose steroid.

Intravenous ceftriaxone with either oral methyl prednisolone or intravenous dexamethasone was given

DRUGOral anti-coagulant

Rivaroxaban was given for minimum 4 weeks depending on D dimer levels

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SUPPORTIVE_CARE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

1. COVID -19 positive patients under home quarantine 2. Patients consulting online on the 3rd or 4th day after the onset of symptoms. 3. Patients with oxygen saturation 94% and above.

Exclusion criteria

1. Patients consulting online on or after 5th day of onset of symptoms. 2. Patients with oxygen saturation less than 94% during the initial presentation. 3. Systemic disease known to increase CRP levels.

Design outcomes

Primary

Measure	Time frame	Description
Number of home quarantined COVID -19 positive patients requiring admission in a hospital for hypoxia.	Two weeks from the onset of symptoms.	Oxygen saturation in COVID-19 positive patients was monitored using pulse oximetry at home. Those patients who developed hypoxia (less than 94%) were referred for hospitalization.

Secondary

Measure	Time frame	Description
Number of home quarantined COVID -19 patients developing thromboembolic complications	Four weeks from the time of initial presentation	Thromboembolic complications in COVID-19 positive patients under home quarantine were assessed using an online questionnaire.

Countries

India

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026